398 related articles for article (PubMed ID: 27091408)
21. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.
Kao RL; Truscott LC; Chiou TT; Tsai W; Wu AM; De Oliveira SN
Hum Gene Ther; 2019 Apr; 30(4):413-428. PubMed ID: 30860401
[TBL] [Abstract][Full Text] [Related]
22. Production of thymus and activation-regulated chemokine and macrophage-derived chemokine by CCR4+ adult T-cell leukemia cells.
Shimauchi T; Imai S; Hino R; Tokura Y
Clin Cancer Res; 2005 Mar; 11(6):2427-35. PubMed ID: 15788694
[TBL] [Abstract][Full Text] [Related]
23. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
[TBL] [Abstract][Full Text] [Related]
25. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
26. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
27. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
28. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
29. Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma.
Nakashima M; Tanaka Y; Okamura H; Kato T; Imaizumi Y; Nagai K; Miyazaki Y; Murota H
Cells; 2024 Jan; 13(2):. PubMed ID: 38247820
[TBL] [Abstract][Full Text] [Related]
30. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with adult T-cell leukemia.
Uno H; Kawano K; Matsuoka H; Tsuda K
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):730-9. PubMed ID: 2618548
[TBL] [Abstract][Full Text] [Related]
31. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
[TBL] [Abstract][Full Text] [Related]
32. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
[TBL] [Abstract][Full Text] [Related]
33. Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia.
Ureshino H; Shindo T; Nishikawa H; Watanabe N; Watanabe E; Satoh N; Kitaura K; Kitamura H; Doi K; Nagase K; Kimura H; Samukawa M; Kusunoki S; Miyahara M; Shin-I T; Suzuki R; Sakaguchi S; Kimura S
Cancer Immunol Res; 2016 Aug; 4(8):644-9. PubMed ID: 27215229
[TBL] [Abstract][Full Text] [Related]
34. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
35. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
36. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
[TBL] [Abstract][Full Text] [Related]
38. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
[TBL] [Abstract][Full Text] [Related]
39. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y
Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259
[TBL] [Abstract][Full Text] [Related]
40. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]